Generess Fe Patent Expiration

Generess Fe is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 06, 2019. Details of Generess Fe's patents and their expiration are given in the table below.

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6667050 Chewable oral contraceptive
Apr, 2019

(7 years ago)

Expired
US5552394 Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
Jul, 2014

(12 years ago)

Expired


FDA has granted several exclusivities to Generess Fe. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Generess Fe, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Generess Fe.

Exclusivity Information

Generess Fe holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Generess Fe's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 22, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Generess Fe is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Generess Fe's family patents as well as insights into ongoing legal events on those patents.

Generess Fe's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Generess Fe's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 06, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Generess Fe Generic API suppliers:

Ethinyl Estradiol; Norethindrone is the generic name for the brand Generess Fe. 18 different companies have already filed for the generic of Generess Fe, with Barr having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Generess Fe's generic

Alternative Brands for Generess Fe

There are several other brand drugs in the same treatment category and using the same active ingredient (Ethinyl Estradiol; Norethindrone) as Generess Fe. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Teva Branded Pharm
Seasonale Used for contraception in women.
Seasonique Used for preventing pregnancy in women using oral contraceptives.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ethinyl Estradiol; Norethindrone. Given below is the list of those drugs and companies owning them.



Apart from brand drugs containing the same ingredient, some generics have also been filed for Ethinyl Estradiol; Norethindrone, Generess Fe's active ingredient. Check the complete list of approved generic manufacturers for Generess Fe





About Generess Fe

Generess Fe is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. Generess Fe uses Ethinyl Estradiol; Norethindrone as an active ingredient. Generess Fe was launched by Teva in 2010.

Approval Date:

Generess Fe was approved by FDA for market use on 22 December, 2010.

Active Ingredient:

Generess Fe uses Ethinyl Estradiol; Norethindrone as the active ingredient. Check out other Drugs and Companies using Ethinyl Estradiol; Norethindrone ingredient

Dosage:

Generess Fe is available in tablet, chewable form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.025MG;0.8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, CHEWABLE Discontinued ORAL